Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine?

 Serum of animals belonging to the Camelidae family (camels and llamas) contains fully active antibodies that are naturally devoid of light chains. Variable domains derived from heavy chain antibodies (hcAb) called VHHs or nanobodies™ can bind antigens as effectively as full-length antibodies and are easy to clone and express. Because of their potential, VHHs are being intensively studied as potential therapeutic, diagnostic and imaging tools. The paper reviews the molecular background of heavy chain antibodies and describes methods of obtaining recombinant fragments of heavy chain antibodies as well as their therapeutic, diagnostic and other applications.

[1]  L. Wyns,et al.  Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody* , 2001, The Journal of Biological Chemistry.

[2]  C. Vanhove,et al.  Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. , 2011, Contrast media & molecular imaging.

[3]  Hamid Rajabi Memari,et al.  Production and characterization of anti‐(mucin MUC1) single‐domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi) , 2007, Biotechnology and applied biochemistry.

[4]  L. Wyns,et al.  LOSS OF SPLICE CONSENSUS SIGNAL IS RESPONSIBLE FOR THE REMOVAL OF THE ENTIRE CH1 DOMAIN OF THE FUNCTIONAL CAMEL IGG2A HEAVY-CHAIN ANTIBODIES' , 1999 .

[5]  B. Jilma,et al.  Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases , 2010, British journal of pharmacology.

[6]  C. Sautès-Fridman,et al.  Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. , 2008, Protein engineering, design & selection : PEDS.

[7]  P. D. de Groot,et al.  A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. , 2005, Blood.

[8]  C. Cambillau,et al.  Lateral recognition of a dye hapten by a llama VHH domain. , 2001, Journal of molecular biology.

[9]  C. Cambillau,et al.  Camelid heavy-chain variable domains provide efficient combining sites to haptens. , 2000, Biochemistry.

[10]  M. Cristina Cardoso,et al.  A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins*S , 2008, Molecular & Cellular Proteomics.

[11]  C. MacKenzie,et al.  A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1. , 2007, Molecular immunology.

[12]  Kalle Gehring,et al.  Protein quality control in the ER: the recognition of misfolded proteins. , 2010, Seminars in cell & developmental biology.

[13]  G. Leroux-Roels,et al.  Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies. , 2010, The Journal of general virology.

[14]  R. Stevens,et al.  A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. , 2010, Journal of molecular biology.

[15]  H. Karoui,et al.  Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins. , 2003, Toxicon : official journal of the International Society on Toxinology.

[16]  H. Sprong,et al.  The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells , 2005, Journal of neurochemistry.

[17]  T. T. Wu,et al.  Length distribution of CDRH3 in antibodies , 1993, Proteins.

[18]  L. Wyns,et al.  Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoire , 2000, The EMBO journal.

[19]  M. Flajnik,et al.  Structural analysis, selection, and ontogeny of the shark new antigen receptor (IgNAR): identification of a new locus preferentially expressed in early development , 2002, Immunogenetics.

[20]  J. Kearney,et al.  The role of immunoglobulin heavy chain binding protein in immunoglobulin transport. , 1987, Immunology today.

[21]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[22]  R. Weiss,et al.  Generation of a Family-specific Phage Library of Llama Single Chain Antibody Fragments That Neutralize HIV-1* , 2010, The Journal of Biological Chemistry.

[23]  S. Muyldermans,et al.  Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. , 2006, Nature medicine.

[24]  S. Muyldermans,et al.  VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. , 2008, Molecular immunology.

[25]  L. Xia,et al.  Molecular Imprint of Enzyme Active Site by Camel Nanobodies , 2012, The Journal of Biological Chemistry.

[26]  A. Desmyter,et al.  Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase , 2009, Protein science : a publication of the Protein Society.

[27]  Austin Hughes,et al.  A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks , 1995, Nature.

[28]  S. Muyldermans,et al.  Single domain camel antibodies: current status. , 2001, Journal of biotechnology.

[29]  S. Muyldermans,et al.  Antigen-Binding Repertoire Single-Domain Antibody Contributes to the A Novel Promiscuous Class of Camelid , 2010 .

[30]  G. Vriend,et al.  Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo , 2005, Applied and Environmental Microbiology.

[31]  A. Plückthun,et al.  Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. , 1999, Biochemistry.

[32]  Sandrine Moutel,et al.  Utilisation des intrabodies : de l’étude des protéines intracellulaires à l’immunisation thérapeutique , 2009 .

[33]  J. W. Bos,et al.  Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. , 2000, Journal of biotechnology.

[34]  E. Remaut,et al.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[35]  M. Seman,et al.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity , 2009, Medical Microbiology and Immunology.

[36]  Nick Deschacht,et al.  A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels? , 2011, PLoS biology.

[37]  A. Sonnenberg,et al.  Reverse proteomic antibody screening identifies anti adhesive VHH targeting VLA-3. , 2009, Molecular immunology.

[38]  C. Verrips,et al.  Preventing phage lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama. , 2002, Journal of dairy science.

[39]  Lode Wyns,et al.  Three Camelid VHH Domains in Complex with Porcine Pancreatic α-Amylase , 2002, The Journal of Biological Chemistry.

[40]  R. Leurs,et al.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells , 2010, Proceedings of the National Academy of Sciences.

[41]  R. Kontermann,et al.  Cell selection and characterization of a novel human endothelial cell specific nanobody. , 2009, Molecular immunology.

[42]  J. Kelly,et al.  A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. , 2004, Journal of molecular biology.

[43]  J. Weissman,et al.  Road to Ruin: Targeting Proteins for Degradation in the Endoplasmic Reticulum , 2011, Science.

[44]  Davoud Ahmadvand,et al.  Nanobody; an Old Concept and New Vehicle for Immunotargeting , 2011, Immunological investigations.

[45]  Sylvain Moineau,et al.  Llama Antibodies against a Lactococcal Protein Located at the Tip of the Phage Tail Prevent Phage Infection , 2005, Journal of bacteriology.

[46]  A. Desmyter,et al.  Functional heavy-chain antibodies in Camelidae. , 2001, Advances in immunology.

[47]  J. A. Garza,et al.  Llama Single Domain Antibodies Specific for the 7 Botulinum Neurotoxin Serotypes as Heptaplex Immunoreagents , 2010, PloS one.

[48]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[49]  Mark C. Field,et al.  High Affinity Nanobodies against the Trypanosome brucei VSG Are Potent Trypanolytic Agents that Block Endocytosis , 2011, PLoS pathogens.

[50]  L. Wyns,et al.  Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies , 2004, Journal of Biological Chemistry.

[51]  C. Sautès-Fridman,et al.  Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. , 2007, Protein engineering, design & selection : PEDS.

[52]  R. Weiss,et al.  Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 , 2008, Journal of Virology.

[53]  J. Boonstra,et al.  Specific production rate of VHH antibody fragments by Saccharomyces cerevisiae is correlated with growth rate, independent of nutrient limitation. , 2005, Journal of biotechnology.

[54]  G. Sutherland,et al.  Kinetic analysis of novel mono‐ and multivalent VHH‐fragments and their application for molecular imaging of brain tumours , 2010, British journal of pharmacology.

[55]  R. Zimmermann,et al.  Functions and pathologies of BiP and its interaction partners , 2009, Cellular and Molecular Life Sciences.

[56]  M. Simoons,et al.  The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention , 2011, Thrombosis and Haemostasis.

[57]  L. Wyns,et al.  Comparison of llama VH sequences from conventional and heavy chain antibodies. , 1997, Molecular immunology.

[58]  D. Wahner-Roedler,et al.  Heavy chain diseases. , 2005, Best practice & research. Clinical haematology.

[59]  R. Weiss,et al.  Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. , 2011, The Journal of infectious diseases.

[60]  Yaofeng Zhao,et al.  Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. , 2006, The Journal of infectious diseases.

[61]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[62]  Jamshid Tanha,et al.  Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. , 2004, Journal of molecular biology.

[63]  A. Allameh,et al.  Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. , 2006, Molecular immunology.

[64]  C. Vanhove,et al.  SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.

[65]  C. Duyckaerts,et al.  Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. , 2009, Molecular immunology.

[66]  Lode Wyns,et al.  Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme , 1996, Nature Structural Biology.

[67]  P. Stanssens,et al.  Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. , 2011, Blood.

[68]  L. Frenken,et al.  The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation , 1999, Immunogenetics.

[69]  Y. F. Frei,et al.  OSMOTIC FRAGILITY OF RED BLOOD CELLS OF YOUNG AND MATURE DOMESTIC AND LABORATORY ANIMALS. , 1964, American journal of veterinary research.

[70]  S. Muyldermans,et al.  Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. , 2009, The Biochemical journal.

[71]  S. Muyldermans,et al.  Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. , 1994, Protein engineering.

[72]  Heinrich Leonhardt,et al.  Targeting and tracing antigens in live cells with fluorescent nanobodies , 2006, Nature Methods.

[73]  E. Remaut,et al.  Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis , 2010, Mucosal Immunology.

[74]  Serge Muyldermans,et al.  Efficient cancer therapy with a nanobody-based conjugate. , 2004, Cancer research.

[75]  M. Rasaee,et al.  Expression and characterization of a recombinant single-domain monoclonal antibody against MUC1 mucin in tobacco plants. , 2006, Hybridoma.

[76]  Christian Vanhove,et al.  Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT , 2008, Journal of Nuclear Medicine.

[77]  S. Muyldermans,et al.  Antibody repertoire development in camelids. , 2006, Developmental and comparative immunology.

[78]  J. Frère,et al.  β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae , 2001, Antimicrobial Agents and Chemotherapy.

[79]  T. Niewold,et al.  Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy , 2006, Applied Microbiology and Biotechnology.

[80]  J. Ladenson,et al.  Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. , 2006, Analytical chemistry.

[81]  Serge Muyldermans,et al.  Efficient tumor targeting by single‐domain antibody fragments of camels , 2002, International journal of cancer.

[82]  L. Wyns,et al.  Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. , 2005, Journal of molecular biology.

[83]  M. Flajnik,et al.  Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Flajnik,et al.  Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: possible role in antigen-driven reactions in the absence of germinal centers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  A. G. Brevern,et al.  A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines , 2010, Cellular and Molecular Life Sciences.

[86]  S. Muyldermans,et al.  A bispecific nanobody to provide full protection against lethal scorpion envenoming , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.